{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Estradiol', 'X', 'X', 'X', 'aPTT, PT/INR', 'X', 'Urinalysis', 'X', 'Metastatic', 'Xi', 'X', 'X', 'biopsy', 'Blood for', 'Exploratory', 'X', 'X', 'X', 'biomarkers', 'Quality of Life', 'Every 3', 'X', 'X', 'X', 'Surverys', 'Cyclesh', 'Brief Pain', 'X', 'X', 'X', 'X', 'Every Cycle', 'Inventory', 'Longterm', 'survival follow', 'X', 'up', 'Adverse events', 'X', 'Abbreviations: CBC, Complete blood count with platelets and differential; CMP, complete metabolic panel (Sodium, Potassium, Chloride, BUN, Serum Creatinine, Calcium, Total Protein, Albumin, Total Bilirubin, AST,', 'ALT,', 'Alkaline Phosphatase, CO2); ECG, electrocardiogram; PSA, prostate-specific antigen; aPTT, activated partial thromboplastin time; PT, prothombin time; INR, international normalized ratio.', 'a. If a study assessment/test was done during the screening period, it does not need to be repeated if within 7 days of Cycle 1, Day 1.', 'b. End of Study visit may replace Follow Up visit if it occurs at 30 days', 'c. Long-term follow up to confirm if patient is still alive, and to document the date of death if deceased. This may be conducted in person or remotely (e.g. via phone, email or postal). Long-term follow up will occur up', 'to 2 years following last dose of study drug(s)', 'd. ECGs are required within 7 days prior to starting study treatment and when clinically indicated.', 'e. CT chest/abodmen/pelvis and bone scan.', 'f. Refer to section 6.3 of the protocol for details', 'g. FACT-P and IIEF surveys', 'h. Beginning Cycle 7, Day 1', 'i. Fresh metastatic tissue is preferred. However, if a biopsy cannot be safely performed, archival tissue obtained within the last year may be used as long as patient had CRPC at the time. For patients with PSA >20', 'ng/ml, plasma derived ctDNA may be used.', 'j. Biopsy and exploratory blood draw at this time point will be optional.', '45(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '6.', 'STUDY ASSESSMENTS', '6.1', 'Efficacy', 'Efficacy will be determined by assessing PSA and radiographic changes (e.g. bone scan, CT', 'scan) while on study. Ideally, these assessments will be performed at SCCA/UWMC,', 'however, if necessary due to extenuating circumstances (e.g. insurance coverage issues) these', 'may be performed at an outside lab/imaging center.', '6.2', 'Safety', 'The Principal Investigator (Michael Schweizer, MD) is responsible for ensuring that all staff', 'involved in the study are familiar with the content of this section.', '6.2.1', 'Definition of adverse events', 'An adverse event is the development of an undesirable medical condition or the deterioration', 'of a pre-existing medical condition following or during exposure to a pharmaceutical product,', 'whether or not considered causally related to the product. An undesirable medical condition', 'can be symptoms (eg, nausea, chest pain), signs (eg, tachycardia, enlarged liver) or the', 'abnormal results of an investigation (eg, laboratory findings, electrocardiogram). In clinical', 'studies, an AE can include an undesirable medical condition occurring at any time, including', 'run-in or washout periods, even if no study treatment has been administered.', 'The term AE is used to include both serious and non-serious AEs.', '6.2.2', 'Olaparib adverse events of special interest', 'Adverse events of special interest [AESI] are events of scientific and medical interest specific', \"to the further understanding of olaparib's safety profile and require close monitoring and rapid\", 'communication by the investigators to AstraZeneca. An AESI may be serious or non-serious.', 'Adverse Events of Special Interest for olaparib are the Important Potential Risks of', 'MDS/AML, new primary malignancy (other than MDS/AML) and pneumonitis.', 'ANY event of MDS/AML, new primary malignancy, or pneumonitis should be reported to', 'AstraZeneca Patient Safety whether it is considered a non-serious AE [eg non-melanoma skin', \"cancer] or SAE, and regardless of investigator's assessment of causality or knowledge of the\", 'treatment arm.', 'A questionnaire will be sent to any investigator reporting an AESI, as an aid to provide further', 'detailed information on the event. During the study there may be other events identified as', 'AESIs that require the use of a questionnaire to help characterise the event and gain a better', 'understanding regarding the relationship between the event and study treatment.', '6.2.3', 'Assessment of severity', 'Assessment of severity is one of the responsibilities of the sub-investigators and Principal', 'Investigator in the evaluation of AEs and SAEs. Severity will be graded according to the NCI', '46(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}